4//SEC Filing
Peraza Lisa 4
Accession 0001209191-23-053030
CIK 0000818033other
Filed
Oct 16, 8:00 PM ET
Accepted
Oct 17, 7:57 PM ET
Size
18.9 KB
Accession
0001209191-23-053030
Insider Transaction Report
Form 4
Peraza Lisa
VP, Chief Accounting Officer
Transactions
- Exercise/Conversion
Common Stock
2023-07-25+42,631→ 67,941 total - Tax Payment
Common Stock
2023-07-25$1.51/sh−14,743$22,262→ 53,198 total - Exercise/Conversion
Common Stock
2023-10-13+552→ 53,750 total - Tax Payment
Common Stock
2023-10-13$0.72/sh−860$619→ 54,822 total - Exercise/Conversion
Performance Stock Units
2023-07-25−42,631→ 0 total→ Common Stock (42,631 underlying) - Exercise/Conversion
Restricted Stock Units
2023-10-13−552→ 2,208 total→ Common Stock (552 underlying) - Exercise/Conversion
Restricted Stock Units
2023-10-13−1,932→ 7,964 total→ Common Stock (1,932 underlying) - Exercise/Conversion
Common Stock
2023-10-13+1,932→ 55,682 total
Footnotes (5)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
- [F3]On July 25, 2022, the Compensation Committee of the Issuer (the "Committee") granted the Reporting Person Performance Stock Units ("PSUs"), the vesting of which was subject to the achievement of certain corporate performance goals and time-based vesting. On January 18, 2023, the Committee determined that certain performance goals of the PSUs had been achieved. The PSUs were further subject to a time-based vesting schedule. The PSUs vested in full on the first anniversary of the grant date (July 25, 2023).
- [F4]The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).
- [F5]The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).
Documents
Issuer
HERON THERAPEUTICS, INC. /DE/
CIK 0000818033
Entity typeother
Related Parties
1- filerCIK 0001828266
Filing Metadata
- Form type
- 4
- Filed
- Oct 16, 8:00 PM ET
- Accepted
- Oct 17, 7:57 PM ET
- Size
- 18.9 KB